Candel: CAN-2409 final phase 2 data shows median OS 31.4 mo vs 12.5 mo in pancreatic cancer

Candel Therapeutics, Inc.

Estimated median overall survival 31.4 months in CAN-2409 arm vs 12.5 months in control (borderline resectable PDAC).
Three of seven CAN-2409-treated patients still alive at data cut-off (66.0, 63.6, 35.8 months post-enrollment).
Median survival post-progression was 21.2 months with CAN-2409 vs 7.2 months in control arm.
No dose-limiting toxicities or pancreatitis; favorable safety profile.
Company plans to advance CAN-2409 into a larger late-stage randomized trial in PDAC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.